Joseph Townley, MD
Ophthalmology · Omaha, NENPI 1972533743
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 170 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 33.4% of the total.
Across 170 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Bausch & Lomb Americas Inc.$377
- Biotissue Holdings Inc.$267
- Alcon$266
- Sun Pharmaceutical Industries Inc.$225
- Bausch & Lomb, A Division Of Bausch Health US, LLC$202
- plus $906 from 17 others
What the payments were for
- Food & beverage$3,35099%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 75 | $1,125 |
| Bausch & Lomb Americas Inc. | 20 | $377 |
| Biotissue Holdings Inc. | 3 | $267 |
| Alcon | 8 | $266 |
| Sun Pharmaceutical Industries Inc. | 10 | $225 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $202 |
| Rayner Intraocular Lenses Limited | 7 | $160 |
| Oyster Point Pharma, Inc. | 9 | $148 |
| Optos, Inc. | 1 | $107 |
| Sight Sciences, Inc. | 3 | $107 |
| Novartis | 5 | $84 |
| Aerie Pharmaceuticals, Inc. | 4 | $59 |
| Stryker | 1 | $36 |
| Rxsight Inc | 2 | $31 |
| The Cameron-ehlen Group, Inc. | 2 | $25 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $25 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Topcon Healthcare, Inc. | 1 | $18 |
| Carl Zeiss Meditec USA, Inc. | 1 | $18 |
| Dompe US, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Glaukos Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$233
- AmnioGraft$233
- PANORAMIC OPHTHALMOSCOPE$215
- PanOptix$137
- LUMIGAN$125
- RESTASIS$109
- OCT OPHTHALMOSCOPE$107
- NFC-700$107
How this compares
$3,367 in reported general payments places this provider in the 85th percentile of 105 ophthalmology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 80 | $88,111 |
| XiidraLifitegrast | 23 | $34,985 |
| LumiganBimatoprost | 88 | $34,454 |
| CequaCyclosporine | 24 | $33,245 |
| VyzultaLatanoprostene Bunod | 63 | $26,714 |
| MieboPerfluorohexyloctane/Pf | 27 | $20,947 |
| Cyclosporine | 20 | $13,322 |
| CombiganBrimonidine Tartrate/Timolol | 31 | $9,011 |
| RocklatanNetarsudil Mesylat/Latanoprost | 19 | $6,358 |
| Latanoprost | 405 | $4,709 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $4,256 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 88 | $1,223 |
| Prednisolone Acetate | 31 | $971 |
| Timolol Maleate | 128 | $955 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 76 | $945 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,125 | $131,576199 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $377 | $82,646113 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $225 | $33,24524 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $59 | $6,35819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 105 ophthalmology providers in Nebraska.
Other ophthalmology in Omaha
- Brandon BaartmanOmaha$226K
- Ronald KruegerOmaha$224K
- Lorraine ProvencherOmaha$220K
- Lance KuglerOmaha$41K
- Rao ChunduryOmaha$14K
- Shane HavensOmaha$6K
- Brandon MenkeOmaha$6K
- Sao LiuOmaha$5K
- Michael HalstedOmaha$4K
- Thomas HejkalOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.